Free shipping on all orders over $ 500

PD-1/PD-L1-IN-NP19 

Cat. No. M29576

All AbMole products are for research use only, cannot be used for human consumption.

PD-1/PD-L1-IN-NP19  Structure

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects.

Chemical Information
Molecular Weight 555.06
Formula C33H31ClN2O4
CAS Number 2377916-66-8
Form Solid
Solubility (25°C) DMSO 2 mg/mL (ultrasonic)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yunzhou Pu, et al. Front Immunol. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression

[2] Chinmoy Ghosh, et al. J Cancer. A snapshot of the PD-1/PD-L1 pathway

[3] Yanyan Han, et al. Am J Cancer Res. PD-1/PD-L1 pathway: current researches in cancer

[4] Nyanbol Kuol, et al. Immunotherapy. PD-1/PD-L1 in disease

[5] Xinxin Zhu, et al. Oncotarget. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

Related PD-1/PD-L1 Products
PD-1/PD-L1-IN-9

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.

NSC622608 

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.

PD-L1-IN-1 

PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM.

SL-279252

SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.

Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

  Catalog
Abmole Inhibitor Catalog




Keywords: PD-1/PD-L1-IN-NP19  supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.